NCT05234307招募中1 期
A Phase Ib Trial of PBF-1129 and Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
Dwight Owen2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2022年11月21日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Incidence of adverse events
研究概览
简要总结
This phase I trial studies the side effects and best dose of PBF-1129 in combination with nivolumab in treating patients with non-small cell lung cancer that has come back (recurrent) or spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as PBF-1129 and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
详细描述
PRIMARY OBJECTIVE:
I. To determine the safety and tolerability of the combination of adenosine A2B receptor antagonist PBF-1129 (PBF-1129) and nivolumab in patients with advanced non-small cell lung cancer (NSCLC) based upon the Common Terminology Criteria for Adverse Events (CTCAE) version 5 criteria.
SECONDARY OBJECTIVE:
I. To determine the efficacy of the combination of PBF-1129 and nivolumab in patients with advanced NSCLC, including progression-free survival (PFS), objective response (ORR), disease control rate (DCR), and overall survival (OS) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
EXPLORATORY OBJECTIVES:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >= 18 years
- •Confirmed recurrent or metastatic non-small cell carcinoma of the lung of any histology without curative options
- •Measurable disease based on RECIST 1.1
- •Patients must have received standard of care chemotherapy and immunotherapy. No limits to prior lines of therapy. Prior PD-1 and/or PD-L1 directed therapies are required. Prior CTLA4 therapy is permitted. Patients may have received no more than 3 prior lines of therapy in the metastatic setting (excluding targeted therapies)
- •Patients with known actionable mutations with Food and Drug Administration (FDA)-approved treatment options must have received all approved and standard of care treatment options (ie osimertinib for EGFR, alectinib for ALK, etc)
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- •Absolute neutrophil count (ANC) >= 1,500 /mcL
- •Platelets >= 100,000 / mcL
- •Serum creatinine OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) =< 1.5 X upper limit of normal (ULN) OR >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN
- •Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN
- •AAspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 X ULN OR =< 5 X ULN for subjects with liver metastases
- •Albumin >= 2.5 mg/dL
- •International normalized ratio (INR) or prothrombin time (PT) or activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants =< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
- •Anticipated life expectancy of >= 3 months
- •Willing to comply with study procedures
- •Must be able to swallow pills
- •Female subjects of childbearing potential must be willing to use an adequate method of contraception
- •For female patients of childbearing potential, a negative serum pregnancy test within 7 days prior to first dose of protocol therapy is required
- •Be willing and able to understand and sign the written informed consent document
- •Availability of a recent formalin-fixed, paraffin-embedded (FFPE) tumor tissue block. A recently obtained archival FFPE tumor tissue block (if an FFPE tissue block cannot be provided, 15 unstained slides (10 minimum) will be acceptable) from a primary or metastatic tumor resection or biopsy can be provided if it was obtained within 1 year of trial screening. Patients with archival tissue that does not meet this criteria may still be eligible in the dose escalation cohort only upon approval from PI.
- •For patients in dose expansion cohort: Be willing to provide tissue from a pre-treatment and on-treatment fin needle aspirate (FNA) or core biopsy of a tumor lesion. Subjects must consent to pre-treatment and on-treatment biopsy prior to initiation of clinical trial, however subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may still continue on study
- •Be willing to provide peripheral blood samples for correlative studies
排除标准
- •Has active autoimmune disease, including myasthenic syndrome, which has required systemic treatment in the past 12 months (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided that disease is well controlled at baseline and requires only topical corticosteroids.
- •Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (at a dose > 10 mg prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment
- •Known active chronic infections - human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), known active (ie with detectable polymerase chain reaction [PCR]) Hepatitis B or C
- •Cirrhosis (Child-Pugh B or worse) or cirrhosis with history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis
- •Symptomatic central nervous system (CNS) metastases. Patients with treated brain metastases are eligible if they are clinically stable with regard to neurologic function, on stable dose of steroids after cranial irradiation with maximum of 10 mg prednisone equivalent. Treatment (whole brain radiation therapy, focal radiation therapy, and stereotactic radiosurgery) must be completed at least 2 weeks prior to study entry, or after surgical resection performed at least 28 days prior to treatment initiation. Patients with asymptomatic lesions will be eligible if considered appropriate by the treating physician.
- •Pregnancy or breastfeeding
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
- •Any of the following cardiac criteria:
- •Mean resting corrected QT interval (corrected QT [QTc] using Fredericia's formula [QTcF]) > 470 msec (Fridericia's Criteria for Corrected QT interval [QTc] Calculation: Fridericia's formula QTcF = (QT/RR0.33). RR is the time from the interval of 1 QRS complex to the next measured in seconds and is commonly calculated as (60/heart rate [HR])
- •Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiogram (ECG) (e.g., complete left bundle branch block, third degree heart block, second degree heart block
- •Any patient who experience unacceptable toxicity on prior checkpoint inhibitor therapy:
- •>= grade 3 adverse event (AE) related to checkpoint inhibitor with the exception of grade 3 pneumonitis that has resolved to grade 1 at time of study entry.
- •Ongoing >= grade 2 immune-related AE associated with checkpoint inhibitor with the exception of endocrine toxicities as detailed below
- •CNS, ocular or cardiac AE of any grade related to checkpoint inhibitor
- •NOTE: Patients with a prior endocrine AE are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic
研究组 & 干预措施
Treatment (PBF-1129, nivolumab)
Experimental
Patients receive PBF-1129 PO QD and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Adenosine A2B Receptor Antagonist PBF-1129 (Drug)
Treatment (PBF-1129, nivolumab)
Experimental
Patients receive PBF-1129 PO QD and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Biospecimen Collection (Procedure)
Treatment (PBF-1129, nivolumab)
Experimental
Patients receive PBF-1129 PO QD and nivolumab IV on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Nivolumab (Biological)
结局指标
主要结局
Incidence of adverse events
时间窗: Up to 30 days after the last dose of study treatment
Safety will be measured by the occurrence of dose-limited toxicities as well as any other adverse events as defined in Common Terminology Criteria for Adverse Events version 5. Frequency and severity of adverse events and tolerability of the regimen will be collected and summarized by descriptive statistics. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. All patients who have received at least one dose of the therapeutic agents will be evaluable for toxicity and tolerability.
次要结局
- Progression free survival(Up to 1 year after treatment discontinuation)
- Overall survival(Up to 1 year after treatment discontinuation)
- Overall objective response rate(Up to 1 year after treatment discontinuation)
- Disease control rate(Up to 1 year after treatment discontinuation)
研究者
Dwight Owen
Principal Investigator
Ohio State University Comprehensive Cancer Center
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionAdvanced Solid Tumor Historically Known for High EphA2 ExpressionUrothelial CancerHead and Neck CancerTriple Negative Breast CancerGastric/Upper Gastrointestinal CancerOvarian CancerNon-small Cell Lung CancerNCT04180371BicycleTx Limited288
已完成
2 期
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial CancerEndometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mucinous AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Squamous Cell CarcinomaEndometrial Transitional Cell CarcinomaEndometrial Undifferentiated CarcinomaMalignant Uterine Corpus Mixed Epithelial and Mesenchymal NeoplasmRecurrent Uterine Corpus CarcinomaNCT01225887Gynecologic Oncology Group37
进行中（未招募）
1 期
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRefractory B Acute Lymphoblastic LeukemiaRefractory Mixed Phenotype Acute LeukemiaNCT02879695National Cancer Institute (NCI)28
进行中（未招募）
1 期
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III MeningiomaGrade 2 MeningiomaGrade 3 MeningiomaRecurrent MeningiomaNCT03604978National Cancer Institute (NCI)38
进行中（未招募）
1 期
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue SarcomaPleomorphic RhabdomyosarcomaResectable Dedifferentiated LiposarcomaResectable Soft Tissue SarcomaResectable Undifferentiated Pleomorphic SarcomaSoft Tissue FibrosarcomaSpindle Cell SarcomaStage I Retroperitoneal Sarcoma AJCC (American Joint Committee on Cancer) v8Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IA Retroperitoneal Sarcoma AJCC v8Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IB Retroperitoneal Sarcoma AJCC v8Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage II Retroperitoneal Sarcoma AJCC v8Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage III Retroperitoneal Sarcoma AJCC v8Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IIIA Retroperitoneal Sarcoma AJCC v8Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IIIB Retroperitoneal Sarcoma AJCC v8Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Storiform-Pleomorphic Malignant Fibrous HistiocytomaUndifferentiated High Grade Pleomorphic Sarcoma of BoneUndifferentiated Pleomorphic SarcomaSynovial SarcomaUndifferentiated Pleomorphic Sarcoma With Osteoclast-Like Giant CellsUndifferentiated Pleomorphic Sarcoma, Inflammatory VariantUndifferentiated Spindle Cell SarcomaMyxofibrosarcomaLeiomyosarcomaMalignant Peripheral Nerve Sheath TumorNCT04420975Jonsson Comprehensive Cancer Center14